Generalized Anxiety Disorder - Epidemiology Forecast to 2030

DelveInsight’s ‘Generalized Anxiety Disorder (GAD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted GAD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Generalized Anxiety Disorder (GAD) Understanding
Generalized Anxiety Disorder (GAD) is characterized by persistent and exaggerated anxiety and worry about everyday life events with no obvious reasons for worry. People with GAD may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with GAD find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. According to Anxiety and Depression Association of America (ADAA), GAD affects around 6.8 million adults or 3.1% of the US adult population in any given year and the criteria used for diagnosis was based on DSM-IV. However, latest DSM-V yielded an influx of new GAD cases which give rise to the prevalence rate as well in adult population (i.e., 12-month prevalence rate is 4% in the US adult population). Women are twice as likely to be affected. GAD can begin at any point in the life cycle but usually develops between childhood and middle age. People with GAD experience a combination of emotional, behavioral, and physical symptoms that often fluctuate, becoming worse at times of stress. The anxiety is often associated with physical symptoms, such as sleep disturbance, restlessness, muscle tension, gastrointestinal symptoms, and chronic headaches and others. It also includes several psychological symptoms.

Epidemiology Perspective by DelveInsight
The GAD epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The GAD epidemiology data are studied through GAD possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted GAD epidemiology [segmented as Total 12-Month Prevalent Cases of GAD, Total Gender-Specific Cases of GAD, Total Age-Specific Cases of GAD, Total Severity -Specific Cases of GAD (Children/Adolescents, and Adults),] scenario of GAD in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

GAD Detailed Epidemiology Segmentation
• The Total 12-Month Prevalent Cases of GAD in 7MM was 16,606,987 in 2017, based on DSM-V criteria. Estimates show that the United States accounted for the highest number of cases of GAD among all the 7MM countries, i.e., 11,113,727. Among the EU5, France has the highest prevalence with estimated 1,304,965 cases in 2017.
• In 2017, there were a total of 4,083,434 cases of GAD in the age-group (18–24), and 685,341 cases in 65 and above, in the United States.
• The severity of GAD Is divided into mild, moderate, or severe based on the number of criteria symptoms such as a functional disability in work role performance, household maintenance, social life, and intimate relationships with the severity of the symptoms.
• In 2017, there were 238,201 mild cases, 459,904 moderate cases and 333,070 severe cases of GAD in the US. The overall children and adolescent specific severity specific cases of GAD are subjected to increase in the coming years.

Scope of the Report
• The GAD report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The GAD Report and Model provide an overview of the risk factors and global trends of GAD in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of GAD in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of GAD.
• The report provides the segmentation of the GAD epidemiology by total 12-Month Prevalent Cases of GAD in the 7MM.
• The report provides the segmentation of the GAD epidemiology by Age and Gender in the 7MM.
• The report provides the segmentation of the GAD epidemiology by Severity-Specific in the 7MM.

Report Highlights
• 11-Year Forecast of GAD epidemiology
• 7MM Coverage
• Total 12-Month Prevalent Cases of GAD in the 7MM
• Prevalent Cases of GAD according to segmentation:Age, Gender, and Severity (Children and Adolescents and Adults)

KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overGADscenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GAD?
• What are the key findings pertaining to the GAD epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of GAD?

Reasons to buy
The GAD epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global GADmarket
• Quantify patient populations in the global GAD market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GAD therapeutics in each of the markets covered
• Understand the magnitude of GAD population by its severity
• The GAD epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The GAD epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Total ptevalent cases of GAD in the United States was assessed to be 11,113,727 in 2017, and are expected to decline during the study period. The severity of GAD Is divided into mild, moderate, or severe based on the number of criteria symptoms such as a functional disability in work role performance, household maintenance, social life, and intimate relationships with the severity of the symptoms. According to DelveInsight’s analysts, the age-specific data in adults, 18–29 is normally reported with the initiation of the anxiety symptoms, thus then increased with middle age group (30–44) and to 45–59 years, while older (60+) age group are the least affected. This may be often associated with societal responsibilities and personal satisfaction levels.


1. Key Insights
2. Executive Summary of Generalized Anxiety Disorder (GAD)
3. SWOT Analysis of GAD
4. Epidemiology Methodology
5. GAD: Disease Background and Overview
5.1. Introduction
5.2. Signs and Symptoms
5.3. Risk Factors and Causes
5.4. Pathophysiology
5.5. Diagnosis
5.6. Screening Tools
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Assumptions and Rationale
6.2.1. United States
6.2.2. EU5
6.2.3. Japan
6.3. Epidemiology: 7MM
6.4. Total 12-Month Prevalent Cases of GAD in 7MM
7. United States
7.1. Total 12-Month Prevalent Cases of GAD in the United States
7.2. Gender-Specific Cases of GAD in the United States
7.3. Age-Specific Cases of GAD in the United States
7.4. Severity -Specific Cases of GAD in the United States
7.4.1. Children and Adolescents
7.4.2. Adults
8. EU5
8.1. Germany
8.1.1. Total 12-Month Prevalent Cases of GAD in Germany
8.1.2. Gender-Specific Cases of GAD in Germany
8.1.3. Age-Specific Cases of GAD in Germany
8.1.4. Severity -Specific Cases of GAD in Germany
8.2. France
8.2.1. Total 12-Month Prevalent Cases of GAD in France
8.2.2. Gender-Specific Cases of GAD in France
8.2.3. Age-Specific Cases of GAD in France
8.2.4. Severity -Specific Cases of GAD in France
8.3. Italy
8.3.1. Total 12-Month Prevalent Cases of GAD in Italy
8.3.2. Gender-Specific Cases of GAD in Italy
8.3.3. Age-Specific Cases of GAD in Italy
8.3.4. Severity -Specific Cases of GAD in Italy
8.4. Spain
8.4.1. Total 12-Month Prevalent Cases of GAD in Spain
8.4.2. Gender-Specific Cases of GAD in Spain
8.4.3. Age-Specific Cases of GAD in Spain
8.4.4. Severity -Specific Cases of GAD in Spain
8.5. The United Kingdom (UK)
8.5.1. Total 12-Month Prevalent Cases of GAD in the UK
8.5.2. Gender-Specific Cases of GAD in the UK
8.5.3. Age-Specific Cases of GAD in the UK
8.5.4. Severity -Specific Cases of GAD in the UK
9. Japan
9.1. Total 12-Month Prevalent Cases of GAD in Japan
9.2. Gender-Specific Cases of GAD in Japan
9.3. Age-Specific Cases of GAD in Japan
9.4. Severity -Specific Cases of GAD in Japan
9.4.1. Children and Adolescents
9.4.2. Adults
10. Appendix
10.1. Bibliography
10.2. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
Table 1 Summary of GAD Epidemiology, and Key Events (2017–2030)
Table 2 “Normal” Worry vs. Generalized Anxiety Disorder
Table 3 Medical Conditions and Medications that Can Cause Anxiety
Table 4 Characteristics to define GAD in DSM-V
Table 5 Evolution of the definition of GAD in succeeding editions of the DSM and ICD
Table 6 Total 12-Month Prevalent Cases of GAD in the 7MM (2017–2030)
Table 7 Total 12-Month Prevalent Cases of GAD in the United States (2017–2030)
Table 8 Gender-Specific Cases of GAD in the United States (2017–2030)
Table 9 Age-Specific Cases of GAD in the United States (2017–2030)
Table 10 Severity-Specific Cases of GAD in Children and Adolescents in the United States (2017–2030)
Table 11 Severity-Specific Cases of GAD in Adults in the United States (2017–2030)
Table 12 Total 12-Month Prevalent Cases of GAD in Germany (2017–2030)
Table 13 Gender-Specific Cases of GAD in Germany (2017–2030)
Table 14 Age-Specific Cases of GAD in Germany (2017–2030)
Table 15 Severity-Specific Cases of GAD in Children and Adolescents in Germany (2017–2030)
Table 16 Severity-Specific Cases of GAD in Adults in Germany (2017–2030)
Table 17 Total 12-Month Prevalent Cases of GAD in France (2017–2030)
Table 18 Gender-Specific Cases of GAD in France (2017–2030)
Table 19 Age-Specific Cases of GAD in France (2017–2030)
Table 20 Severity-Specific Cases of GAD in Children and Adolescents in France (2017–2030)
Table 21 Severity-Specific Cases of GAD in Adults in France (2017–2030)
Table 22 Total 12-Month Prevalent Cases of GAD in Italy (2017–2030)
Table 23 Gender-Specific Cases of GAD in Italy (2017–2030)
Table 24 Age-Specific Cases of GAD in Italy (2017–2030)
Table 25 Severity-Specific Cases of GAD in Children and Adolescents in Italy (2017–2030)
Table 26 Severity-Specific Cases of GAD in Adults in Italy (2017–2030)
Table 27 Total 12-Month Prevalent Cases of GAD in Spain (2017–2030)
Table 28 Gender-Specific Cases of GAD in Spain (2017–2030)
Table 29 Age-Specific Cases of GAD in Spain (2017–2030)
Table 30 Severity-Specific Cases of GAD in Children and Adolescents in Spain (2017–2030)
Table 31 Severity-Specific Cases of GAD in Adults in Spain (2017–2030)
Table 32 Total 12-Month Prevalent Cases of GAD in the UK (2017–2030)
Table 33 Gender-Specific Cases of GAD in the UK (2017–2030)
Table 34 Age-Specific Cases of GAD in the UK (2017–2030)
Table 35 Severity-Specific Cases of GAD in Children and Adolescents in the UK (2017–2030)
Table 36 Severity-Specific Cases of GAD in Adults in the UK (2017–2030)
Table 37 Total 12-Month Prevalent Cases of GAD in Japan (2017–2030)
Table 38 Gender-Specific Cases of GAD in Japan (2017–2030)
Table 39 Age-Specific Cases of GAD in Japan (2017–2030)
Table 40 Severity-Specific Cases of GAD in Children and Adolescents in Japan (2017–2030)
Table 41 Severity-Specific Cases of GAD in Adults in Japan (2017–2030)
Figure 1 GAD SWOT Analysis
Figure 2 Epidemiology Methodology
Figure 3 Overview of GAD
Figure 4 Symptoms and Behaviors Associated with Generalized Anxiety Disorder
Figure 5 Etiology of GAD
Figure 6 Risk factors for GAD
Figure 7 Mental Disorders Screening—General Anxiety Disorder Assessment (GAD-7)
Figure 8 Mental Disorders Screening—Generalized Anxiety Disorder 2-item (GAD-2)
Figure 9 Total 12-Month Prevalent Cases of GAD in the 7MM (2017–2030)
Figure 10 Total 12-Month Prevalent Cases of GAD in the United States (2017–2030)
Figure 11 Gender-Specific Cases of GAD in the United States (2017–2030)
Figure 12 Age-Specific Cases of GAD in the United States (2017–2030)
Figure 13 Severity-Specific Cases of GAD in Children and Adolescents in the United States (2017–2030)
Figure 14 Severity-Specific Cases of GAD in Adults in the United States (2017–2030)
Figure 15 Total 12-Month Prevalent Cases of GAD in Germany (2017–2030)
Figure 16 Gender-Specific Cases of GAD in Germany (2017–2030)
Figure 17 Age-Specific Cases of GAD in Germany (2017–2030)
Figure 18 Severity-Specific Cases of GAD in Children and Adolescents in Germany (2017–2030)
Figure 19 Severity-Specific Cases of GAD in Adults in Germany (2017–2030)
Figure 20 Total 12-Month Prevalent Cases of GAD in France (2017–2030)
Figure 21 Gender-Specific Cases of GAD in France (2017–2030)
Figure 22 Age-Specific Cases of GAD in France (2017–2030)
Figure 23 Severity-Specific Cases of GAD in Children and Adolescents in France (2017–2030)
Figure 24 Severity-Specific Cases of GAD in Adults in France (2017–2030)
Figure 25 Total 12-Month Prevalent Cases of GAD in Italy (2017–2030)
Figure 26 Gender-Specific Cases of GAD in Italy (2017–2030)
Figure 27 Age-Specific Cases of GAD in Italy (2017–2030)
Figure 28 Severity-Specific Cases of GAD in Children and Adolescents in Italy (2017–2030)
Figure 29 Severity-Specific Cases of GAD in Adults in Italy (2017–2030)
Figure 30 Total 12-Month Prevalent Cases of GAD in Spain (2017–2030)
Figure 31 Gender-Specific Cases of GAD in Spain (2017–2030)
Figure 32 Age-Specific Cases of GAD in Spain (2017–2030)
Figure 33 Severity-Specific Cases of GAD in Children and Adolescents in Spain (2017–2030)
Figure 34 Severity-Specific Cases of GAD in Adults in Spain (2017–2030)
Figure 35 Total 12-Month Prevalent Cases of GAD in the UK (2017–2030)
Figure 36 Gender-Specific Cases of GAD in the UK (2017–2030)
Figure 37 Age-Specific Cases of GAD in the UK (2017–2030)
Figure 38 Severity-Specific Cases of GAD in Children and Adolescents in the UK (2017–2030)
Figure 39 Severity-Specific Cases of GAD in Adults in the UK (2017–2030)
Figure 40 Total 12-Month Prevalent Cases of GAD in Japan (2017–2030)
Figure 41 Gender-Specific Cases of GAD in Japan (2017–2030)
Figure 42 Age-Specific Cases of GAD in Japan (2017–2030)
Figure 43 Severity-Specific Cases of GAD in Children and Adolescents in Japan (2017–2030)
Figure 44 Severity-Specific Cases of GAD in Adults in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook